TOI Share Price Performance
US$3.32
2.08 (167.74%)
52.6% undervalued intrinsic discount
US$7.00
Fair Value
Price US$3.32
AnalystConsensusTarget US$7.00
AnalystLowTarget US$5.00
AnalystHighTarget US$8.00
Fair ValueUS$7.00
Share Pricen/a
The Oncology Institute, Inc. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
TOI Community Narratives
AN
Fair Value US$7 52.6% undervalued intrinsic discount
Florida And Nevada Expansions Will Strengthen Community Oncology Care
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value US$5 33.6% undervalued intrinsic discount
Capitation And Pharmacy Pressures Will Test This Model Before Long Term Value Emerges
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$8 58.5% undervalued intrinsic discount
Value Based Oncology Expansion And AI Deployment Will Transform Long Term Earnings Power
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Capitation And Pharmacy Pressures Will Test This Model Before Long Term Value Emerges
Catalysts About Oncology Institute The Oncology Institute provides community based oncology care using a mix of employed clinics, affiliated providers and pharmacy services under value based and fee for service contracts. What are the underlying business or industry changes driving this perspective?Read more
3
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$5
33.6% undervalued intrinsic discount
Fair Value
Profit Margin
5.45%
Future PE
15.16x
Price in 2029
US$6.12
Value Based Oncology Expansion And AI Deployment Will Transform Long Term Earnings Power
Catalysts About Oncology Institute The Oncology Institute delivers value based community oncology care supported by an integrated pharmacy and technology enabled platform. What are the underlying business or industry changes driving this perspective?Read more
11
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$8
58.5% undervalued intrinsic discount
Fair Value
Profit Margin
5.45%
Future PE
24.57x
Price in 2028
US$9.79
Florida And Nevada Expansions Will Strengthen Community Oncology Care
Key Takeaways Rapid expansion of value-based contracts and scaled risk-based care models is driving strong patient growth, margin expansion, and sustainable top-line gains. Market tailwinds, tech investments, and growing pharmacy operations position the company for durable demand, lower costs, and increased profitability.Read more
69
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$7
52.6% undervalued intrinsic discount
Fair Value
Profit Margin
5.39%
Future PE
24.87x
Price in 2028
US$5.48
Trending Discussion
Recently Updated Narratives
AN
Capitation And Pharmacy Pressures Will Test This Model Before Long Term Value Emerges
Fair Value: US$5 33.6% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Value Based Oncology Expansion And AI Deployment Will Transform Long Term Earnings Power
Fair Value: US$8 58.5% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Florida And Nevada Expansions Will Strengthen Community Oncology Care
Fair Value: US$7 52.6% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
The Oncology Institute, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.51
- 15.20%
- -10.01%
- -492.4%
About TOI
- Founded
- 2007
- Employees
- 641
- CEO
- WebsiteView website
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
